Steven Stacker

Prof. Steven Stacker

Head of the Tumor Angiogenesis Program at Peter MacCallum Cancer Centre in Australia, Melbourne

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2001 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Steven StackerSteven Stacker
Steven Stacker
CCCarol Caesar
Carol Caesar
MBMegan E. Baldwin
Megan E. Baldwin
GTGillian E. Thornton
Gillian E. Thornton
RWRichard A. Williams
Richard A. Williams
MAMarc Achen
Marc Achen

20 January 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MAMarc Achen
Marc Achen
Michael JeltschMichael Jeltsch
Michael Jeltsch
EKEola Kukk
Eola Kukk
TMTaija Mäkinen
Taija Mäkinen
AVAngela Vitali
Angela Vitali
Steven StackerSteven Stacker
Steven Stacker
We have identified a member of the VEGF family by computer-based homology searching and have designated it VEGF-D. VEGF-D is most closely related to VEGF-C by virtue of the presence of N- and C-terminal extensions that are not found in other VEGF family members. In adult human tissues, VEGF-D mRNA is most abundant in heart, lung, skeletal muscle, colon, and small intestine. Analyses of VEGF-D receptor specificity revealed that VEGF-D is a ligand for both VEGF receptors (VEGFRs) VEGFR-2 (Flk1) and VEGFR-3 (Flt4) and can activate these receptors. However, VEGF-D does not bind to VEGFR-1. Expression of a truncated derivative of VEGF-D demonstrated that the receptor-binding capacities reside in the portion of the molecule that is most closely related in primary structure to other VEGF family members and that corresponds to the mature form of VEGF-C. In addition, VEGF-D is a mitogen for endothelial cells. The structural and functional similarities between VEGF-D and VEGF-C define a subfamily of the VEGFs.

13 February 2014 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
Steven StackerSteven Stacker
Steven Stacker
SWSteven P. Williams
Steven P. Williams
TKTara Karnezis
Tara Karnezis
RSRamin Shayan
Ramin Shayan
SFStephen Fox
Stephen Fox
MAMarc Achen
Marc Achen

1 December 1990 in Journal of Cell Biology
Verified
Journal Article
Open access
MDM S Diamond
M S Diamond
DSD E Staunton
D E Staunton
AFA R de Fougerolles
A R de Fougerolles
Steven StackerSteven Stacker
Steven Stacker
JGJ Garcia-Aguilar
J Garcia-Aguilar
TST A Springer
T A Springer
While the leukocyte integrin lymphocyte function-associated antigen (LFA)-1 has been demonstrated to bind intercellular adhesion molecule (ICAM)-1, results with the related Mac-1 molecule have been controversial. We have used multiple cell binding assays, purified Mac-1 and ICAM-1, and cell lines transfected with Mac-1 and ICAM-1 cDNAs to examine the interaction of ICAM-1 with Mac-1. Stimulated human umbilical vein endothelial cells (HUVECs), which express a high surface density of ICAM-1, bind to immunoaffinity-purified Mac-1 adsorbed to artificial substrates in a manner that is inhibited by mAbs to Mac-1 and ICAM-1. Transfected murine L cells or monkey COS cells expressing human ICAM-1 bind to purified Mac-1 in a specific and dose-dependent manner; the attachment to Mac-1 is more temperature sensitive, lower in avidity, and blocked by a different series of ICAM-1 mAbs when compared to LFA-1. In a reciprocal assay, COS cells cotransfected with the alpha and beta chain cDNAs of Mac-1 or LFA-1 attach to immunoaffinity-purified ICAM-1 substrates; this adhesion is blocked by mAbs to ICAM-1 and Mac-1 or LFA-1. Two color fluorescence cell conjugate experiments show that neutrophils stimulated with fMLP bind to HUVEC stimulated with lipopolysaccharide for 24 h in an ICAM-1-, Mac-1-, and LFA-1-dependent fashion. Because cellular and purified Mac-1 interact with cellular and purified ICAM-1, we conclude that ICAM-1 is a counter receptor for Mac-1 and that this receptor pair is responsible, in part, for the adhesion between stimulated neutrophils and stimulated endothelial cells.

3 September 2001 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
TMTaija Mäkinen
Taija Mäkinen
TVTanja Veikkola
Tanja Veikkola
SMSatu Mustjoki
Satu Mustjoki
TKTerhi Karpanen
Terhi Karpanen
BCBruno Catimel
Bruno Catimel
KAKari Alitalo
Kari Alitalo
Vascular endothelial growth factor receptor‐3 (VEGFR‐3/Flt4) binds two known members of the VEGF ligand family, VEGF‐C and VEGF‐D, and has a critical function in the remodelling of the primary capillary vasculature of midgestation embryos. Later during development, VEGFR‐3 regulates the growth and maintenance of the lymphatic vessels. In the present study, we have isolated and cultured stable lineages of blood vascular and lymphatic endothelial cells from human primary microvascular endothelium by using antibodies against the extracellular domain of VEGFR‐3. We show that VEGFR‐3 stimulation alone protects the lymphatic endothelial cells from serum deprivation‐induced apoptosis and induces their growth and migration. At least some of these signals are transduced via a protein kinase C‐dependent activation of the p42/p44 MAPK signalling cascade and via a wortmannin‐sensitive induction of Akt phosphorylation. These results define the critical role of VEGF‐C/VEGFR‐3 signalling in the growth and survival of lymphatic endothelial cells. The culture of isolated lymphatic endothelial cells should now allow further studies of the molecular properties of these cells.

1 August 2002 in Nature Reviews Cancer
Verified
Journal Article
Closed access
Steven StackerSteven Stacker
Steven Stacker
MAMarc Achen
Marc Achen
LJLotta Jussila
Lotta Jussila
MBMegan E. Baldwin
Megan E. Baldwin
KAKari Alitalo
Kari Alitalo